BioFIT 2019 conference programme is tailored to fit the expectations of its audience, whose sharp minds evolve in the fast-paced and dynamic Life Sciences sector. Built around 12 sessions and 1 plenary session, the 2019 programme is rooted in three custom-made tracks, addressing the right funding sources for early-stage innovation, best practices in academia-industry R&D collaborations, and nurturing early-stage assets.

Plenary Session

The BioFIT 2019 plenary session will aim to understand the pharma players concerns and their new goals and changing roles in an evolving biotech sector. What does cutting-edge mean for pharma? Pharma are not pure developers anymore, they are companies trying to seek broader solutions to answer the patient needs: What does it mean for the industry? What does it mean for the deals’ orientation? How does pharma now look at combined solutions with technologies? Our panel will discuss this matter during an opening 90-minute session.

BioFIT 2019 also features a conference programme shaped around 3 tracks to match the interests of every player in the sector.

Best practices in academia-industry R&D collaborations

Fostering academia-industry partnerships is key to fuel innovation in the sector. What type of new models to foster collaborations can we find? What are the long-lasting commitments between universities and pharmaceutical players in sharing long-term agenda? What are the elements that need to exist to make them happen? How are the new schemes occurring in the world influencing academia-pharma partnerships? How can these collective efforts question the way the industry is covering the pre-competitive status?

Nurturing and licensing early-stage assets

Early-stage assets evolve in an ecosystem where TTOs, scientists and entrepreneurs are closely connected. This subject will focus on the valuation of assets at an early-stage and on value propositions. How can we fully understand the proposition behind the value? The track aims to underline the difficulties for maturing early-stage assets. How can we transform science into business more frequently and efficiently?

Early-stage innovation: Identify the right funding sources

This track aims to understand the mechanisms enforcing investors’ presence in foreign markets, the inequalities in geographical repartition of investment in Europe. Are we witnessing the apparition of safe havens or favourite therapeutic areas to invest in? Who are the new players involved in investing on the biotech sector and what are their pre-requisites? Are there increasing interactions and partnerships between pharma and VCs at these initial stages?